On this page
What each program costs in Michigan
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | medication monthly, membership yearly | $75/mo | $199/yr, included | 4.8 (288 reviews) | Visit | ||
| 6 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 12 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 13 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 14 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 15 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 16 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 17 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 18 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 19 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does the Michigan State Health Plan (SHP PPO and State HDHP) cover GLP-1s for weight loss?
Since January 1, 2026, Michigan's State Health Plan PPO and State HDHP no longer cover GLP-1 drugs such as Wegovy, Zepbound and Saxenda for weight management or sleep apnea. They stay covered for diabetes and cardiovascular diagnoses.
Michigan Civil Service Commission
The Civil Service Commission's 2026 open enrollment guide says weight-management GLP-1s left the SHP PPO and State HDHP on January 1, 2026, and that earlier weight-management approvals ended December 31, 2025.
“Effective January 1, 2026, GLP-1 inhibitors (e.g., Saxenda, Wegovy, and Zepbound) will no longer be covered under the SHP PPO and State HDHP for weight management or sleep apnea but will continue to be covered for diabetes management and cardiovascular diagnoses. All existing prior authorization approvals for GLP-1 inhibitors with a weight management or sleep apnea diagnosis will end effective December 31, 2025.”
https://www.michigan.gov/mdcs/-/media/Project/Websites/mdcs/EBD/boe/BOE26.pdf · read Oct 29, 2026
Michigan Civil Service Commission
The 2026 retiree bulletin says the same change applies to retirees, except where Medicare requires coverage.
“Beginning January 1, 2026, the SHP will no longer cover the category of drugs known as GLP-1 inhibitors for weight management except when required by Medicare.”
https://www.michigan.gov/mdcs/-/media/Project/Websites/mdcs/EBD/retiree/26RetDB.pdf · read Oct 29, 2026
What do Michigan's big insurers publish on Wegovy and Zepbound?
Blue Cross Blue Shield of Michigan and Blue Care Network
Blue Cross Blue Shield of Michigan and Blue Care Network stopped covering GLP-1s for weight loss, including Wegovy and Zepbound, for fully insured large-group members from January 1, 2025 or the group's 2025 renewal. Self-funded employers set their own rules.
Blue Cross Blue Shield of Michigan
Blue Cross's September 2024 provider alert says weight-loss GLP-1s, including Wegovy and Zepbound, are no longer covered from January 1, 2025 or the group's 2025 renewal date.
“Beginning Jan. 1, 2025, or on the group’s 2025 health coverage renewal date, Blue Cross Blue Shield of Michigan and Blue Care Network will no longer cover prescriptions for glucagon-like peptide-agonist drugs used for weight loss, including Saxenda®, Wegovy® and Zepbound®.”
https://providerinfo.bcbsm.com/documents/alerts/2024/202409/alert-20240927-2025-coverage-change-glp-1-drugs.pdf · read Oct 29, 2026
Blue Cross Blue Shield of Michigan
The change covers fully insured large groups with a prescription drug plan; the alert adds that some self-funded groups have also removed coverage.
“This change applies to Blue Cross and BCN commercial members of fully insured large groups with a prescription drug plan.”
https://providerinfo.bcbsm.com/documents/alerts/2024/202409/alert-20240927-2025-coverage-change-glp-1-drugs.pdf · read Oct 29, 2026
Does Michigan Medicaid cover GLP-1s for weight loss?
Covered, with conditions
Michigan Medicaid covers Wegovy and Zepbound for obesity only under strict rules since January 1, 2026: morbid obesity, failure of other options, and use only to avert bariatric surgery. Read from state documents Nov 6, 2026.
What Michigan Medicaid's documents say about each drug for weight loss. Read Nov 6, 2026. Michigan Department of Health and Human Services.
WegovyYes
Prior authorization, age 12 and older. Adults need BMI 40 or higher. Must fail or be unable to take all five preferred drug types, and use must be only to avert bariatric surgery.
“GLP-1 product coverage requested for treatment of obesity will require additional clinical PA requirements”
Michigan Department of Health and Human Services · Effective Jan 1, 2026 · read Nov 6, 2026
“Prescriber attests patient age ≥18 years and has an initial body mass index (BMI) classified as morbidly obese (e.g., baseline BMI ≥ 40 kg/m2 or greater)”
Prime Therapeutics for Michigan Medicaid · No effective date on the document · read Nov 6, 2026
“Prescriber attests that use of this GLP1 agent for weight loss is considered only as a measure to avert the need for higher-cost bariatric surgery”
Prime Therapeutics for Michigan Medicaid · No effective date on the document · read Nov 6, 2026
ZepboundYes
Prior authorization, age 18 and older. Adults need BMI 40 or higher. Must fail or be unable to take all five preferred drug types, and use must be only to avert bariatric surgery.
“GLP-1 product coverage requested for treatment of obesity will require additional clinical PA requirements”
Michigan Department of Health and Human Services · Effective Jan 1, 2026 · read Nov 6, 2026
“Prescriber attests patient age ≥18 years and has an initial body mass index (BMI) classified as morbidly obese (e.g., baseline BMI ≥ 40 kg/m2 or greater)”
Prime Therapeutics for Michigan Medicaid · No effective date on the document · read Nov 6, 2026
“Prescriber attests that use of this GLP1 agent for weight loss is considered only as a measure to avert the need for higher-cost bariatric surgery”
Prime Therapeutics for Michigan Medicaid · No effective date on the document · read Nov 6, 2026
OzempicNo
Preferred diabetes drug with a clinical edit that requires a type 2 diabetes diagnosis and no other GLP-1 drug.
“MDHHS added a clinical prior authorization edit to the preferred agents that requires a diagnosis of T2D and no concurrent therapy with another GLP-1 agonist”
Michigan Department of Health and Human Services · Effective Feb 1, 2024 · read Nov 6, 2026
“OZEMPIC* SEMAGLUTIDE PEN INJCTR 960”
Michigan Department of Health and Human Services · Effective Sep 2, 2025 · read Nov 6, 2026
MounjaroNot confirmed
The September 2025 DUR materials do not mark Mounjaro as PDL preferred, so the quoted type 2 diabetes edit for preferred agents may not be its rule. Its non-preferred criteria were not found: a guessed criteria URL returned 404.
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Michigan Department of Health and Human Services documents. KFF's January 2026 map listed this program as covered; the documents we read agree.
- Jan 1, 2026 · Policy changeNarrowed coverage of GLP-1 drugs prescribed only for obesity.
“Coverage of GLP-1 medications when prescribed solely to treat obesity, including requests for continuation, will be reduced.”
Michigan Department of Health and Human Services · Effective Jan 1, 2026 · read Nov 6, 2026
Weight loss
Covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
359,212 prescriptions
Ozempic and Mounjaro, 2025
153,539 prescriptions
Neighbours covering weight loss
1 of 3
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Michigan Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Michigan Medicaid as "covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Michigan Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Michigan Medicaid pay for?
607,982 GLP-1 prescriptions in 2025, 4th of the 50 states and DC, with $672.1 million reimbursed before rebates. Counting the share other payers covered, $681.0 million.
Prescriptions, 2025
607,982
4th of 51
Medicaid paid
$672.1M
4th of 51, before rebates
Per prescription
$1,105
$1,051 nationally
Weight-loss brands
59%
2nd highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Michigan is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 59% of Michigan Medicaid's GLP-1 prescriptions in 2025 (359,212). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Wegovy was Michigan Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Wegovyapproved for weight management | 194,841 | 32% | $249.6 million | $1,281 |
| Zepboundapproved for weight management | 161,929 | 27% | $166.9 million | $1,031 |
| Trulicity | 90,652 | 15% | $90.9 million | $1,003 |
| Ozempic | 87,007 | 14% | $87.8 million | $1,009 |
| Mounjaro | 66,532 | 11% | $69.8 million | $1,049 |
| Saxendaapproved for weight management | 2,442 | 0.4% | $2.9 million | $1,207 |
| Rybelsus | 2,292 | 0.4% | $2.7 million | $1,198 |
| Liraglutide (generic) | 1,147 | 0.2% | $604,611 | $527 |
| Victoza | 1,073 | 0.2% | $712,123 | $664 |
| Byetta | 42 | 0.0% | $36,488 | $869 |
| Bydureon | 25 | 0.0% | $21,306 | $852 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
On Medicare in Michigan?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Michigan and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
1 of the 3 states next to Michigan covers GLP-1s for weight loss through Medicaid: Wisconsin. None has a lower cash floor than Michigan's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Michigan | Covered | 19 | $39/mo |
| Indiana | Not covered | 19 | $39/moWellmedr |
| Ohio | Not covered in part | 19 | $39/moWellmedr |
| Wisconsin | Zepbound only | 19 | $39/moWellmedr |






















